NovoCure Ltd Quarterly Debt-to-equity in % from Q2 2016 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: NovoCure Ltd quarterly Debt-to-equity history and growth rate from Q2 2016 to Q3 2024.
NovoCure Ltd Debt-to-equity for the quarter ending September 30, 2024 was 226 %, a 27% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	226	+47.9	+27%	Sep 30, 2024
Q2 2024	213	+42.2	+24.7%	Jun 30, 2024
Q1 2024	199	+31.5	+18.8%	Mar 31, 2024
Q4 2023	188	+23.2	+14%	Dec 31, 2023
Q3 2023	178	+10.7	+6.42%	Sep 30, 2023
Q2 2023	171	+2.14	+1.27%	Jun 30, 2023
Q1 2023	167	-4.89	-2.84%	Mar 31, 2023
Q4 2022	165	-12.5	-7.05%	Dec 31, 2022
Q3 2022	167	+5.49	+3.4%	Sep 30, 2022
Q2 2022	169	+33.9	+25.1%	Jun 30, 2022
Q1 2022	172	+55.7	+47.9%	Mar 31, 2022
Q4 2021	178	+83.3	+88.3%	Dec 31, 2021
Q3 2021	161	+73.7	+84.1%	Sep 30, 2021
Q2 2021	135	+21.9	+19.4%	Jun 30, 2021
Q1 2021	116	-10.1	-8%	Mar 31, 2021
Q4 2020	94.4	-50.7	-34.9%	Dec 31, 2020
Q3 2020	87.7	-77.7	-47%	Sep 30, 2020
Q2 2020	113	-66.4	-37%	Jun 30, 2020
Q1 2020	126	-60.3	-32.3%	Mar 31, 2020
Q4 2019	145	-39.7	-21.5%	Dec 31, 2019
Q3 2019	165	-1.97	-1.18%	Sep 30, 2019
Q2 2019	179	+25	+16.2%	Jun 30, 2019
Q1 2019	187	+47.1	+33.7%	Mar 31, 2019
Q4 2018	185	+64.7	+53.9%	Dec 31, 2018
Q3 2018	167	+56.4	+50.9%	Sep 30, 2018
Q2 2018	154	+54.3	+54.2%	Jun 30, 2018
Q1 2018	140	+63.1	+82.3%	Mar 31, 2018
Q4 2017	120	+64.3	+115%	Dec 31, 2017
Q3 2017	111	+72.7	+190%	Sep 30, 2017
Q2 2017	100	+70.4	+237%	Jun 30, 2017
Q1 2017	76.6			Mar 31, 2017
Q4 2016	55.8			Dec 31, 2016
Q3 2016	38.2			Sep 30, 2016
Q2 2016	29.7			Jun 30, 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.